Improved Survival in Advanced Hepatocellular Carcinoma with Liver Transplantation and ADV-TK Gene Therapy

This study focuses on treating advanced hepatocellular carcinoma, a type of liver cancer, using a combination of liver transplantation and a gene therapy called ADV-TK. The main goal is to improve survival rates and reduce the chance of cancer coming back after treatment. This research is particularly important for patients with this form of advanced liver cancer, as it aims to address current challenges and enhance their care. In this study, participants will receive a liver transplant along with ADV-TK gene therapy. The therapy is designed to help prevent cancer recurrence. The results are measured by tracking survival rates and recurrence-free survival rates at one, two, and three years after treatment. The study shows promising outcomes, with higher survival and lower recurrence rates in the group receiving both liver transplant and ADV-TK therapy compared to those receiving only a transplant. However, it's important to note that the presence of vascular invasion may impact these results.